Abalkhail Adil, AlYami Ahmad S, Alrashedi Saeed F, Almushayqih Khalid M, Alslamah Thamer, Alsalamah Yasir Ahmed, Elbehiry Ayman
Department of Public Health, College of Public Health and Health Informatics, Qassim University, Al Bukayriyah 52741, Saudi Arabia.
King Fahad Medical City, P.O. Box 59046, Riyadh 11525, Saudi Arabia.
Healthcare (Basel). 2022 Sep 15;10(9):1778. doi: 10.3390/healthcare10091778.
The that produces extended-spectrum lactamases (ESBL-) can develop resistance to many antibiotics. The control of ESBL- disorders is challenging due to their restricted therapeutic approaches, so this study aims to determine the prevalence and pattern of the antibiotic resistance of ESBL- among male and female patients with urinary tract infections in Riyadh, Saudi Arabia. During the period of 2019 to 2020 at King Fahd Medical City, Riyadh, 2250 urine samples from patients with urinary tract infections (UTIs) were collected, and microbial species were cultured and identified using standard biochemical techniques. A double-disc synergy test was used to identify ESBL-producing strains of and an in vitro method and the clinical laboratory standard institute (CLSI) criteria were employed to determine the resistance of these strains to antimicrobial drugs. ESBL- was detected in 510 (33.49%) of the 1523 isolates, 67.27% of which were recovered from women and 33.7% of which were recovered from men. A total of 284 (55.69%) ESBL- isolates were found in patients under 50 years of age, and 226 (44.31%) were found in patients over 50 years of age. Nearly all the isolates of ESBL- were resistant to cephalosporins (ceftriaxone, cefotaxime, cefepime, cefuroxime, and cephalothin) and penicillin (ampicillin), whereas the majority of the isolates were sensitive to several carbapenems (imipenem, meropenem, and ertapenem), aminoglycosides (amikacin), and nitrofurantoins. The development of antibiotic resistance by ESBL-, the most frequent pathogen linked to urinary tract infections, plays a crucial role in determining which antibiotic therapy is appropriate.
产超广谱β-内酰胺酶(ESBL-)的[细菌名称未给出]可对多种抗生素产生耐药性。由于治疗方法有限,控制ESBL-感染具有挑战性,因此本研究旨在确定沙特阿拉伯利雅得尿路感染男性和女性患者中ESBL-的抗生素耐药率及模式。2019年至2020年期间,在利雅得法赫德国王医疗城,收集了2250份尿路感染(UTIs)患者的尿液样本,并使用标准生化技术对微生物种类进行培养和鉴定。采用双纸片协同试验鉴定产ESBL-的[细菌名称未给出]菌株,并使用体外方法和临床实验室标准协会(CLSI)标准来确定这些菌株对抗菌药物的耐药性。在1523株[细菌名称未给出]分离株中,检测到510株(33.49%)产ESBL-,其中67.27%从女性患者中分离得到,33.7%从男性患者中分离得到。在50岁以下患者中,共发现284株(55.69%)产ESBL-分离株,在50岁以上患者中发现226株(44.31%)。几乎所有产ESBL-的分离株都对头孢菌素(头孢曲松、头孢噻肟、头孢吡肟、头孢呋辛和头孢噻吩)和青霉素(氨苄西林)耐药,而大多数分离株对几种碳青霉烯类药物(亚胺培南、美罗培南和厄他培南)、氨基糖苷类药物(阿米卡星)和呋喃妥因敏感。产ESBL-作为尿路感染最常见的病原体,其抗生素耐药性的产生在确定合适的抗生素治疗方面起着关键作用。